Pioglitazone/glimepiride: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 25: | Line 25: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 17:38, 18 March 2025
Pioglitazone/Glimepiride is a combination medication used in the treatment of Type 2 diabetes. It contains two active ingredients, Pioglitazone and Glimepiride, which work together to control blood sugar levels in individuals with this condition.
Etymology[edit]
The name "Pioglitazone" is derived from its chemical structure, which includes a pyridine ring and a thiazolidinedione nucleus. "Glimepiride" is derived from its chemical structure as well, which includes a sulfonylurea moiety.
Mechanism of Action[edit]
Pioglitazone is a thiazolidinedione that decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Glimepiride lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing potassium channels in the beta-cell membrane, leading to cell depolarization and an influx of calcium ions.
Side Effects[edit]
Common side effects of Pioglitazone/Glimepiride include hypoglycemia, weight gain, and fluid retention. Less common but more serious side effects can include liver disease, anemia, and heart failure.
